Sign in
CompletedNo phase

Dual Anti-glutamate Therapy in Super-refractory Status Epilepticus After Cardiac Arrest

Key facts

Who runs it
University of Milano Bicocca
Where
Italy10 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
84 people enrolled
Started
15 Jan 2022
Ended
31 Dec 2025
Type of study
Observational, 2 groups
Treatments tested
  • Ketamine
  • Any anti-epileptic and anesthetic therapy, excluding Ketamine and Perampanel
Record updated
14 July 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • age ≥ 18 years
  • patients in coma after cardio-circulatory arrest (CCA) admitted to the Intensive Care Unit and treated with target temperature management (TTM) for the first 24 hours
  • initiation of continuous electroencephalographic (cEEG) monitoring within 24-36 hours of CCA
  • diagnosis of super-refractory status epilepticus, relapsed after the first cycle of anesthetics (lasting > 24 hours) and antiepileptic therapy, defined according to the international Salzburg criteria9
  • presence of pupillary reflex present bilaterally
  • presence of N20 cortical response present bilaterally

Who cannot take part

  • EEG with periodic pattern (generalized periodic discharges; GPDs)
  • status epilepticus resolved after the first cycle of anesthetics + antiepileptics
  • pregnant women

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Status epilepticus (SE) is found in 20-30% of patients in coma after cardiac arrest, is often refractory to medical therapy and is considered a negative prognostic factor. Intensity and duration of treatment of refractory and super-refractory post-anoxic SE pose the ethical dilemma between futility of treatments and, conversely, their premature suspension. A recent study by the Epilepsy Center of the San Gerardo Hospital has shown that patients with super-refractory post-anoxic SE and favorable prognostic indicators can achieve a good functional outcome in more than 40% of cases, if treated with intensive and protracted therapy.

Read full original descriptionShow less

However, there is profound uncertainty about the best combination of antiseizure medications and anesthetics to use in this condition. A combined anti-glutamatergic therapy with ketamine (anti-NMDA receptor) and perampanel (anti-AMPA receptor), aimed at counteracting the excitotoxicity linked to global cerebral ischemia, could be particularly effective in the treatment of super-refractory SE with post-anoxic etiology. Preliminary results in the first 26 patients treated in the Coordinating Center of the project indicate that this therapy appears safe and highly effective (80% SE resolution, 40% good neurological outcome).

The aim of the SUPER-CAT study is to investigate the efficacy and safety of combined therapy with ketamine and perampanel (dual anti-glutamatergic therapy) in patients with post-anoxic super-refractory status epilepticus, compared to other therapies, using a multi-centre, retrospective, cohort study design.

The 2 groups in the trial

  • Dual anti-glutamate therapy (DUAL)

    Patients who received ketamine as a continuous i.v. for 3 days (induction dose 1.5-3 mg/kg, followed by maintenance dose 2-10 mg/kg/h; dose adjustment according to EEG target of "ketamine pattern") + oral perampanel via nasogastric tube for 5 days (12 mg if weight \> 60 kg; 9 mg if weight 50-60 kg; 6 mg if weight \< 50 kg), followed by gradual dose reduction according to clinical evolution.

    Treatment: Ketamine

  • Control (OTHERS)

    Patients who received any antiseizure and anesthetic therapy according to usual clinical practice, excluding the two anti-glutamate drugs ketamine and perampanel.

    Treatment: Any anti-epileptic and anesthetic therapy, excluding Ketamine and Perampanel

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
SUPER-refractory Status Epilepticus After Cardiac Arrest: a Multicenter, Retrospective, Cohort Study of Dual Anti-glutamate Therapy With Ketamine and Perampanel
Publications
Record updated
14 July 2026